

Twenty-Five Years of AI in Neurology: The Journey of Predictive Medicine and Biological Breakthroughs

Barak Gutman, Amit-Haim Shmilovitch^{bsc}, Shahr Shelly

Submitted to: Journal of Medical Internet Research
on: April 15, 2024

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript..... 5

Supplementary Files..... 51

..... 51

Figures 52

Figure 1..... 53

Figure 2..... 54

Figure 3..... 55

Figure 4..... 56

Twenty-Five Years of AI in Neurology: The Journey of Predictive Medicine and Biological Breakthroughs

Barak Gutman¹ BSc; Amit-Haim Shmilovitch^{2,3} BSc; Shahr Shelly^{2,3,4} MD

¹Faculty of Biology, Technion - Israel Institute of Technology Haifa IL

²Department of Neurology, Rambam Medical Center Haifa IL

³Neuroimmunology Laboratory, Ruth and Bruce Rapaport Faculty of Medicine, Technion – Israel Institute of Technology Haifa IL

⁴Department of Neurology, Mayo Clinic Rochester US

Abstract

Neurological disorders are the leading cause of physical and cognitive disability across the globe, currently affecting up to 15% of the world population, with burden of chronic neurodegenerative diseases doubled over the last two decades. Two decades ago, neurologists relying solely on clinical signs and basic imaging faced challenges in diagnosis and treatment. Today, the integration of artificial intelligence and bioinformatic methods are changing this landscape. This review explores this transformative journey, emphasizing the critical role of bioinformatics in neurology, which we term as Neuroinformatics, aiming to integrate a multitude of methods and thereby enhance the field of neurology.

Over the past 25 years, the integration of biomedical data science into medicine, particularly neurology, has fundamentally transformed how we understand, diagnose, and treat neurological diseases. Advances in genomics sequencing, the introduction of new imaging methods, the discovery of novel molecular biomarkers for nervous system function, a comprehensive understanding of immunology and neuroimmunology shaping disease subtypes, and the advent of advanced electrophysiological recording methods, alongside the digitalization of medical records and the rise of AI, all led to an unparalleled surge in data within neurology. Additionally, telemedicine and virtual health platforms, accelerated by the COVID-19 pandemic, have become integral to neurology practice. The real-world impact of these advancements is evident, with AI-driven analysis of imaging and genetic data leading to earlier and more accurate diagnoses of conditions like Multiple Sclerosis, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Alzheimer's Disease and more.

Neuroinformatics is the key component connecting all these advances. By harnessing the power of information technology and computational methods to efficiently organize, analyze, and interpret vast datasets, we can extract meaningful insights from complex neurological data, contributing to a deeper understanding of the intricate workings of the brain. In this review, we describe the large-scale datasets that have emerged in neurology over the last 25 years and showcase the major advancements made by integrating these datasets with advanced neuroinformatic approaches for the diagnosis and treatment of neurological disorders. We further discuss challenges in integrating AI into neurology, including ethical considerations in data use, the need for further personalization of treatment, and embracing new emerging technologies like quantum computing. These developments are shaping a future where neurological care is more precise, accessible, and tailored to individual patient needs. We believe further advancements in neuroinformatics will bridge traditional medical disciplines and cutting-edge technology, navigating the complexities of neurological data and steering medicine toward a future of more precise, accessible, and patient-centric healthcare.

(JMIR Preprints 15/04/2024:59556)

DOI: <https://doi.org/10.2196/preprints.59556>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.
Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.
Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in <http://www.jmir.org/preprint/59556>, the full manuscript will be available to all users.



Original Manuscript

Twenty-Five Years of AI in Neurology: The Journey of Predictive Medicine and Biological Breakthroughs

Barak Gutman¹; Amit Haim Shmilovitch^{2,4}; Dvir Aran PhD^{*1,3}; Shahar Shelly MD^{*2,4,5}

* Equal last authors

¹ Faculty of Biology, Technion - Israel Institute of Technology, Haifa, Israel

² Department of Neurology, Rambam Medical Center, Haifa, Israel

³ The Taub Faculty of Computer Science, Technion - Israel Institute of Technology, Haifa, Israel

⁴ Neuroimmunology Laboratory, Ruth and Bruce Rapaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, 3525408, Israel.

⁵ Department of Neurology, Mayo Clinic, Rochester, Minnesota

Corresponding authors: 1. Shahar Shelly

Department of Neurology, Rambam Medical Center, Haifa, Israel

E-mail: s_shelly@rmc.gov.il

Keywords: Neurology; Artificial intelligence; Telemedicine; Clinical advancements.

Abstract

Neurological disorders are the leading cause of physical and cognitive disability across the globe, currently affecting up to 15% of the world population, with burden of chronic neurodegenerative diseases doubled over the last two decades. Two decades ago, neurologists relying solely on clinical signs and basic imaging faced challenges in diagnosis and treatment. Today, the integration of artificial intelligence (AI) and bioinformatic methods is changing this landscape. This review explores this transformative journey, emphasizing the critical role of artificial intelligence in neurology, aiming to integrate a multitude of methods and thereby enhance the field of neurology.

Over the past 25 years, the integration of biomedical data science into medicine, particularly neurology, has fundamentally transformed how we understand, diagnose, and treat neurological diseases. Advances in genomics sequencing, the introduction of new imaging methods, the discovery of novel molecular biomarkers for nervous system function, a comprehensive understanding of immunology and neuroimmunology shaping disease subtypes, and the advent of advanced electrophysiological recording methods, alongside the digitalization of medical records and the rise of AI, all led to an unparalleled surge in data within neurology. Additionally, telemedicine and virtual health platforms, accelerated by the COVID-19 pandemic, have become integral to neurology practice. The real-world impact of these advancements is evident, with AI-driven analysis of imaging and genetic data leading to earlier and more accurate diagnoses of conditions like Multiple Sclerosis, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Alzheimer's Disease and more.

Neuroinformatics is the key component connecting all these advances. By harnessing the power of information technology and computational methods to efficiently organize, analyze, and interpret vast datasets, we can extract meaningful insights from complex neurological data, contributing to a deeper understanding of the intricate workings of the brain. In this review, we describe the large-scale datasets that have emerged in neurology over the last 25 years and showcase the major advancements made by integrating these datasets with advanced neuroinformatic approaches for the diagnosis and treatment of neurological disorders. We further discuss challenges in integrating AI into neurology, including ethical considerations in data use, the need for further personalization of treatment, and embracing new emerging technologies like quantum computing. These developments are shaping a future where neurological care is more precise, accessible, and tailored to individual patient needs. We believe further advancements in AI will bridge traditional medical disciplines and cutting-edge technology, navigating the complexities of neurological data and steering medicine toward a future of more precise, accessible, and patient-centric healthcare.

Introduction

Neurological disorders are a leading cause of disability and mortality worldwide, affecting millions of individuals worldwide, and placing a significant burden on healthcare systems. In 2019, these disorders were responsible for nearly 10 million deaths and 349 million Disability-adjusted life-years (DALYs) globally, with stroke and neonatal encephalopathy being the primary contributors [1,2]. Over the past three decades, the prevalence of neurological disorders has increased substantially, particularly in low- and middle-income countries, and this trend is expected to continue as populations age [1]. However, we have also witnessed remarkable advancements in technology and data science that are transforming the field of neurology. These developments offer new hope for improving the diagnosis, treatment, and management of neurological disorders. This review explores the evolving landscape of neurology, focusing on how the integration of cutting-edge technologies and vast datasets is revolutionizing our understanding of neurological disorders and paving the way for more personalized, effective, and accessible care.

In the past 25 years, numerous technological advancements have significantly impacted the field of neurological medicine. These include the integration of new sophisticated imaging technologies that provide deeper insights into brain anatomy and physiological and functional, advanced electrophysiological brain-maps that create detailed maps of brain regions and connectivity, advances in neurogenetics and molecular biology that help identify and characterize various neurological conditions, and the development of telemedicine, which enables physicians to provide better and more convenient treatment, among others.

Specifically, one of the most notable advancements has been the widespread adoption of electronic health records (EHRs). EHRs have not only transformed clinical practice but also opened up vast opportunities for research by creating large datasets that can be analyzed using advanced data science techniques. The integration of EHRs with other data sources, such as imaging and genetic data, has enabled researchers to identify novel disease subtypes, predict patient outcomes, and develop personalized treatment strategies. Another area where technology has made significant strides is in the development of novel diagnostic tools and biomarkers. For example, advances in neuroimaging techniques, such as functional MRI and PET scans, have allowed for earlier and more accurate diagnosis of neurological diseases. Similarly, the discovery of new genomic and molecular biomarkers has paved the way for more targeted therapies and precision medicine approaches.

Furthermore, the increasing availability of large-scale neurological datasets, coupled with advancements in machine learning and AI opened new possibilities for predictive and decision support systems. These tools can assist clinicians in making more accurate diagnoses, predicting disease progression, and optimizing treatment plans based on individual patient characteristics.

It is important to acknowledge that while this review aims to provide a comprehensive overview of the impact of AI on neurology, its scope is necessarily limited. We have focused on key areas that, in our assessment, have most significantly influenced the field of neurology over the past quarter-century. The subsequent five chapters of this review dive deeper into these advancements, exploring how they are reshaping the landscape of neurological care and research (**Figure 1 and Figure 2**). Rather than attempting an exhaustive analysis of each topic, our goal is to highlight the current state of the art, identify pressing challenges and promising opportunities, and suggest potential future directions within each domain. By doing so, we hope to provide a balanced perspective on the transformative potential of AI in neurology, while also recognizing the vast and rapidly evolving nature of this field. This review serves as a starting point for further exploration and discussion, acknowledging that the integration of AI in neurology is an ongoing journey with many exciting developments yet to come.

The Digital Transformation of Neurological Evaluation: From Bedside Physical Examination to Data-Driven Diagnostics

The transition from traditional physical examination to digital data acquisition and patient triage in outpatient clinics marks a significant paradigm shift in neurological evaluation. It is widely accepted that a meticulous patient history is crucial for achieving an accurate and timely diagnosis, with estimates suggesting that 70% to 90% of medical diagnoses can be determined by the history alone [3]. This, combined with a physical examination and a comprehensive understanding of neuroanatomy, constitutes a traditional approach to neurological diagnosis, primarily aimed at pinpointing the disease's anatomical location. The specific features that make neurology unique include a heavy reliance on complex physical examination for diagnosis and follow-up; utilization of specialty-specific neurophysiologic testing (e.g., electromyography [EMG]/nerve conduction studies [NCS], electroencephalogram [EEG], sensory evoked potential studies and sensory evoked potentials [SEP]); high utilization of neuroradiologic imaging (i.e., magnetic resonance imaging - MRI, computer tomography- CT); use of videotaped examinations by clinicians for movement disorders; utility of patient-recorded videos or pictures in the medical record (e.g., seizures, pseudo-

seizures, tics, dyskinesias); and importance of patient documentation of episodic complaints (e.g., migraines, seizures).

While traditional approaches have been the backbone of neurological practice, the rapid growth of digital technologies and the increasing volume of patient data have necessitated a shift in how neurologists approach diagnosis and treatment. The digitization of medical records, in particular, has been a game-changer, allowing clinicians to capture, store, and analyze vast amounts of patient information in ways that were previously unimaginable. This transition has not only improved the efficiency and accuracy of neurological care but has also opened up new avenues for research and discovery.

The adoption of EHRs has been a gradual process, driven by advances in computing technology and the recognition of their potential to improve patient care. The journey began in the 1960s with the earliest attempts to digitize patient information, but it was not until the 1990s that EMRs began to gain widespread traction. In the 1990s, the rise of more affordable, powerful, and compact computing technologies, alongside the increasing use of local area networks and the internet, catalyzed the development and adoption of electronic health/medical records, also known as EHR [4]. Initially, EHRs were predominantly deployed in academic medical facilities, containing only partial medical information, with the remainder still documented on paper [5]. These early systems were mainly hosted on large mainframes with limited functionalities, focusing on laboratory and medication [6]. Their adoption faced challenges due to high costs, data-entry errors, and only partial acceptance by physicians [7]. At this stage, EHRs were primarily used for data interchange among doctors [8] and for image scanning and documentation [9], with clinical usage increasing as computers became more integrated into healthcare as "physician workstations" [10].

There has been rapid adoption of EHRs over the last few years, spurred in large part by financial incentives allocated by the Health Information Technology for Economic and Clinical Health Act as part of the American Recovery and Reinvestment Act of 2009. In the years that have since passed the global use and reliance on EHR in the departments such as in the emergency department (ED) have grown stronger. By 2015, EHRs had gained recognition from major medical organizations and governments as essential for storing patient data to optimize care delivery [11]. This application endowed the hospital with improved web/client-server-based systems with relational databases, facilitating easier data access and the sharing of medical information through health information exchange (HIE) networks [12]. This period also saw efforts to standardize EHRs internationally, allowing for a common set of data exchange standards and terminology. In outpatient clinics, there is

a consensus that the integration of EHR has resulted in a significant reduction in overall waiting times and a decrease in documentation errors [13].

Improved patient care and triage in neurology

The implementation of EHR system has fundamentally altered both research paradigms and clinical workflows for neurologists (**Figure 3**). The EHR system, by its very design, has transformed the way neurologists compose clinical notes, often replacing individualized communication styles with template-based entries that aggregate vast amounts of data with minimal effort. Neurologists have written about the challenges of EHR use with many published articles discussing the difficulties in neurology practice. Recent publications report concerns with the efficiency of the use of EHRs in academic practice, challenges of implementation, improper documentation, issues of privacy, and impairing the physician-patient relationship.

The adoption of EHR has had a significant impact on the field of neurology, along with the broader medical community, influencing everything from clinical practice and patient care to research and administration. EHR systems have standardized the documentation process, making it easier to maintain consistency across patient records. This is particularly beneficial in neurology, where the complexity of neurological conditions requires detailed recording of clinical findings, treatment plans, and patient responses. However, the standardization can sometimes lead to a loss of individual clinician's nuances in documenting their observations and thought processes, potentially impacting the richness of the clinical narrative. Another area is accessibility and coordination of care, which allows for easier access to patient records across different healthcare settings, which is crucial for neurology patients who often require multidisciplinary care. This accessibility improves coordination among healthcare providers, leading to more integrated care plans and better patient outcomes. Furthermore, EHR systems have facilitated the growth of telemedicine, which has become especially important for neurology patients with mobility issues or those living in remote areas. One overwhelming success is the wealth of data captured in EHRs that can be a gold mine for neuroinformatic research and the development of predictive models for neurological diseases. This aspect is particularly relevant in academic and research settings where EHR data can be analyzed to uncover patterns, predict outcomes, and guide the development of new treatment protocols [14].

Prediction models using electronic records.

In this current era of big data, the focus has shifted towards leveraging the vast databases of EHRs through AI and machine learning technologies. This involves developing AI algorithms for predicting patient risk and personalized treatment plans [15]. One example is a study that focuses on

addressing the gap in predicting post-stroke seizures, a significant concern in neurology given stroke's role as a leading cause of acquired epilepsy in adults. The researchers aimed to develop and validate a prognostic model, named the SeLECT score, for predicting the risk of late seizures (occurring more than 7 days after) in individuals who have suffered an ischemic stroke. The SeLECT score was developed through a multivariable prediction model using data from 1,200 participants in Switzerland and validated externally in 1,169 participants across Austria, Germany, and Italy. It incorporates five clinical predictors: severity of stroke, large-artery atherosclerotic etiology, early seizures, cortical involvement, and territory of middle cerebral artery involvement. The model's effectiveness was demonstrated by its ability to stratify the risk of late seizures post-stroke, with a concordance statistic of 0.77 in validation cohorts, indicating good predictive accuracy. This approach exemplifies the potential of predictive models to transform patient care in neurology by enabling tailored interventions based on individual risk assessments [16].

Another example is a study that introduces a statistical model designed to improve the diagnosis of immune-mediated necrotizing myopathy (IMNM), a condition where delayed diagnosis can lead to significant morbidity. IMNM diagnosis is particularly challenging in patients with a chronic course who lack specific markers making the assessment of immunotherapy response difficult. The model leverages electrical myotonia versus fibrillations as biomarkers to predict immunotherapy treatment response, based on data from 119 cases of IMNM and 938 other myopathy patients. All subjects underwent electrophysiological evaluations, muscle biopsies, neurological examinations, and creatine kinase measurements [17]. In the broader context of predictive models in neurology, this study exemplifies how statistical models can significantly enhance the diagnosis and treatment of neurological conditions. By identifying specific biomarkers and incorporating them into a predictive framework, such models offer a path toward more personalized and timely interventions. This approach mirrors the potential seen in the SeLECT score for predicting post-stroke seizures, further illustrating the critical role of predictive models in advancing neurology practice.

Predictive models may also incorporate other types of data, including imaging, biomarkers, and environmental and lifestyle factors. The scope of predictive models is broad; in cerebral hemodynamics, they focus on assessing cerebral autoregulation to determine the optimal cerebral perfusion pressure (CPP) for individual patients. For example, the PRx index [18] uses data from ventricular catheters [19] or intraparenchymal devices [20]. Cerebral metabolism is another area benefiting from predictive analytics, with algorithms analyzing brain interstitial fluid via intracerebral microdialysis to detect metabolic distress, anaerobic metabolism, cell injury, and membrane breakdown. This monitoring facilitates early detection of metabolic changes and guides

therapeutic interventions [21]. Additionally, predictive analytics play a critical role in brain oxygenation monitoring, ensuring a balance between oxygen supply and demand. The primary methods in this field include direct brain tissue oxygen tension monitoring [22], jugular venous bulb oximetry [23,24], and near-infrared spectroscopy (NIRS) [25]. Moreover, in recent years, the development of predictive analytics for neurologic disorders has seen significant advancements. For instance, researchers have derived a single "Alzheimer's Disease Identification Number" from clinical and neuroimaging data, offering a novel approach to tracking disease severity [26]. In multiple sclerosis (MS), a developed predictive model can identify MS subtypes through MRI data and unsupervised machine learning [27]. In Parkinson's disease, predictive models have identified antitumor necrosis factor therapy as a potential therapeutic option for mitigating disease risk among patients with inflammatory bowel disease (IBD) [28]. These advanced analytics methods demonstrate improved accuracy and prognostication over traditional models, offering new insights into patient management and treatment outcomes in neurovascular research.

This shift towards healthcare institutions taking on the responsibility for developing decision-support tools marks a significant point in the regulatory environment and the need for tailored solutions. At the same time, the global healthcare sector is increasingly tapping into EHR data for AI-based projects, aiming to utilize the vast amount of medical data to enhance patient outcomes through disease prediction, treatment personalization, and the acceleration of new drug discovery especially in neurology. These efforts require strict protocols for data standardization, processing, and privacy to maximize the benefits of AI research while protecting sensitive patient information. Supported by initiatives like those from the Korean government[29,30], there's a growing movement towards leveraging AI in healthcare, pointing towards a future where AI, powered by EHR data, becomes central to advancing medical research and delivering personalized care to patients.

Creation of large accessible datasets

Despite the critical importance of training databases, there is a lack of publicly accessible, reliable datasets. This shortage primarily results from data sharing barriers across institutions, the time and cost of data annotation, and occasionally the complexity of building data processing pipelines. Training data may be pre-annotated, a process known as "supervised learning," or it may not be, which is referred to as "unsupervised learning." In the realm of AI in healthcare, supervised learning models are predominantly utilized due to the critical nature of their applications, where human lives hinge on the accuracy of AI outputs. To address this issue, several national and multi-national data banks have emerged, covering various neurological conditions [31]. During 2013-2014, several

governments initiated national initiatives aimed at understanding brain function, such as the NIH Brain Initiative in the US [32], the Brain Project in Europe [33], and the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) project in Japan [34]. Many of them soon became global and involved collecting and analyzing voluminous data including neuroimaging, genetic, biospecimen, and/or clinical assessments to unlock and decipher genesis and prognosis of neurological conditions. As the collection of data became increasingly prominent, the need for procedures, standards, hardware, and software for data-intensive computing increased [35]. These projects leverage big data to explore the brain structure ("connectome") and function with the ultimate goal of developing new treatments for neurological diseases.

For instance, the Alzheimer's Disease Neuroimaging Initiative (ADNI), which launched in 2005, aims to identify biomarkers for the early detection and monitoring of Alzheimer's Disease (AD). It supports interventions, prevention, treatments through early diagnostics, and facilitates global data sharing [36,37]. By collecting and analyzing data on cognitive functions, brain structure, metabolism (via PET and MRI scans), genetics, and biochemical changes in a diverse cohort, ADNI has provided significant contributions. Its most substantial contribution to date is the development of methodologies for the early diagnosis of AD, utilizing biomarker tests such as amyloid PET scans and CSF lumbar punctures. This approach has revealed a significant number of individuals in their mid-70s showing preclinical stages of AD [38], underscoring the critical importance of early prevention and treatment strategies for the disease.

In parallel, the ENIGMA Consortium [39], established in 2009, represents another pivotal big data initiative in the field of neuroscience. It aims to integrate neuroimaging and genetic data to investigate brain genotype-phenotype relationships. ENIGMA's notable achievements include identifying genome-wide variants related to brain imaging phenotypes [40,41] and examining MRI-based abnormalities across various conditions [39,42], such as major depressive disorder [43] and bipolar disorder [44]. These discoveries have substantially improved diagnostics and patient care, showcasing the value of integrating big data in advancing neuroscience research.

Beyond the contributions of major organizations, recent years have witnessed the emergence of numerous big data-driven diagnostic solutions in neuroscience from smaller entities. Key discoveries include the identification of multiple sclerosis (MS) subtypes using sophisticated imaging analyses and improvements in MRI data [27] and unsupervised machine learning, as well as the differentiation of dementia subtypes through the analysis of multimodal data from ADNI [45]. Additionally, significant strides have been made in depression research, highlighted by the successful prediction of

treatment response through various methods: connectome gradient dysfunction paired with gene expression [46], resting state connectivity markers of Transcranial Magnetic Stimulation (TMS) response [47], and a sertraline-response electroencephalogram (EEG) signature [48]. In terms of migraine research, the Italian I-GRAINE registry is being developed to serve as a comprehensive source of clinical, biological, and epidemiologic big data. This registry aims to enhance our understanding of therapeutic response rates and the efficacy of treatments [49]. Another notable diagnostic initiative is the iPrognosis mobile app, designed to expedite the diagnosis of Parkinson's disease (PD) and improve the quality of life for PD patients. The app functions by collecting data during the user's interaction with smart devices, including smartphones and smartwatches, showcasing the innovative use of technology in patient care and research [50].

In summary, over the past decade, numerous emerging AI technologies have significantly enhanced patient flow through various means. These advancements range from facilitating direct intrahospital communication to autonomously analyzing radiological images and assisting in the selection of patients for specialized treatments. The development and refinement of these AI systems rely heavily on access to extensive data banks, which serve as foundational resources for training purposes. Such repositories, both large and small, have already yielded substantial improvements in the diagnosis of numerous neurological conditions. The trend towards leveraging big data is expected to intensify, with the emergence of larger databases in the coming years. This expansion will be further supported by an increasing volume of data collected through wearable technology. Consequently, these databases will play a crucial role in enabling the development of new AI-driven approaches for treatment and diagnosis [51].

New Communication Technologies: Telemedicine and Remote Patient Monitoring

As powerful as AI-mediated medical treatment is, it still does not fully address growing demand for neurologic care, which is exacerbated by a shortage of neurologists. This challenge is expected to intensify with the expanding aging population, highlighting the urgent need for a more substantial neurologic care provision. Telemedicine emerges as a promising solution to bridge this gap, offering access to those hindered by geographical or physical barriers, such as mobility issues (**Figure 3**). It facilitates earlier access to specialized care, potentially reducing the strain on patients and caregivers while enhancing patient satisfaction. Additionally, telemedicine provides an avenue for neurologists facing social, physical, or health-related challenges to maintain or extend their practice, including those considering part-time work or retirement. It also allows for more efficient use of neurologists' time by eliminating travel between facilities, thereby increasing availability for patient evaluations

and the ability to serve remote clinics. Telemedicine leverages a wide array of technologies, including two-way videoconferencing, data storage and forwarding, and mobile and wireless devices, to deliver care more flexibly and efficiently [52]. Despite previous barriers to telemedicine adoption, such as reimbursement issues, recent policy changes by the Centers for Medicare & Medicaid Services, which expanded Medicare-covered telehealth services for 2019, have significantly improved access to neurologic care. These changes not only enhance patient care options but also open new revenue streams for neurologists, signaling a shift towards a more accessible and sustainable model of neurologic care delivery [53,54].

Virtual consultations

Telestroke services, first described in 1999 and formally integrated into stroke care systems for over a decade, have significantly influenced the broader field of telemedicine. This period has seen expanded access to care, improvements in quality, and higher rates of reperfusion therapy for patients with ischemic stroke. [55] Additionally, comparisons between telestroke and in-person evaluations have shown similar rates of stroke mimics, indicating that assessment scales and imaging interpretations are just as effective when conducted remotely [56]. Telestroke's acceptance across diverse cultures further underscores its effectiveness and potential for broader application. However, despite these strides in enhancing stroke care through telemedicine, there remains a gap in data regarding the suitability and practicality of telemedicine for treating other neurological conditions [57], highlighting an area ripe for exploration and development.

Another example is in neuromuscular conditions encompasses a wide range of disorders, from common diabetic neuropathy to rare diseases such as periodic paralysis. Many of these conditions, including amyotrophic lateral sclerosis (ALS), necessitate a comprehensive, multidisciplinary management approach. Despite rapid advancements in diagnostic technologies, the accurate diagnosis of many neuromuscular disorders often hinges on detailed neurologic examinations to detect subtle clinical signs that might be overlooked in teleneurology assessments. However, telemedicine has been found beneficial for patients with established diagnoses and stable symptoms, offering a convenient option for follow-up evaluations [58]. Research on the use of teleneurology specifically for neuromuscular disorders is limited, and only a handful of studies have been published to date. These studies, primarily focused on patients with a confirmed diagnosis of ALS [59], revealed a generally positive perception of teleneurology among patients, caregivers, and healthcare providers. Patients expressed high levels of satisfaction, appreciating particularly the elimination of travel-related burdens which led to less stress and more comfortable medical

interactions. Additionally, a smaller study involving patients with advanced facioscapulohumeral muscular dystrophy indicated that teleneurology was well-received by both patients and caregivers [57]. The quality of care provided via teleneurology was rated highly in patient questionnaires, though it's noted that acute care issues were not addressed in these evaluations.

There are other examples such as concussions and traumatic brain injuries [60,61], dementia evaluations [62], and the management and follow-up of epilepsy patients [63,64]. It has also facilitated the diagnosis and treatment of non-acute headaches [65–67], assessment of movement disorders [68–70], remote care for Multiple Sclerosis [71,72] as well as follow-up consultations and care management for neuromuscular patients [52,73]. The COVID-19 pandemic saw a rush in telemedicine use across specialties to manage patient care during lockdowns, mask mandates, and overall minimization of personal interactions. This era is characterized by the adoption of telemedicine on a national scale, exemplified by Saudi Arabia's adoption of telemedicine as an alternative health delivery system [74], and the launch and deployment of a telemedicine program by the Italian government [75]

Improving patient flow and early detection

Stroke is a highly prevalent neurological disorder, affecting approximately 9.4 million Americans over the age of 20 between 2017 and 2020 [76]. More than half of stroke patients were left chronically disabled [77], and the annual mortality rate as of 2020 was 160 thousand Americans [76]. For many years stroke diagnosis was significantly hampered by time delays between the initial detection at radiologic centers and subsequent treatment at thrombectomy centers within hospitals. As of 2016, this delay averaged nearly 100 minutes in the U.S., leading to increased morbidity [78] and disability [79]. In response to this challenge, AI company developed a convolutional neural network (CNN) algorithm capable of automatically detecting ischemic stroke patterns associated with large vessel occlusions (LVOs) [80]. Upon identifying an LVO, the algorithm autonomously alerts the stroke treatment team, bypassing the need for any intervention by the clinician who requested the radiologic examination. Alerts are dispatched through a mobile application, facilitating immediate communication and resulting in an average reduction of 52 minutes in the time to LVO treatment initiation [81]. Beyond facilitating direct communication, modern AI-based telestroke systems enhance patient flow by autonomously analyzing radiological images, often surpassing the capabilities of human radiologists [82]. Clinical AI today is adept at interpreting CT and MRI scans to determine the size and extent of brain damage caused by ischemic strokes [82], and can even forecast the potential progression of the stroke [83].

AI has also augmented radiologist performance by aiding in the selection of patients for endovascular thrombectomy. This is achieved through the integration of automated Alberta Stroke Program Early CT Scores (ASPECTS) with clinical presentations, thereby correlating with the National Institutes of Health Stroke Scale (NIHSS) scores [84,85]. Moreover, AI proves its proficiency in acute prognosis prediction by evaluating detected infarct volumes [86] or white matter hyperintensities [87]. It even enables predicting treatment outcomes [85,88,89] with remarkable accuracy, including a notable 7% improvement in forecasting symptomatic intracerebral hemorrhage [90]. These advancements highlight AI's broad application in stroke care, from the analysis of radiological imaging to the identification of stroke indicators, enhancing intrahospital communication and significantly contributing to the decision-making process for timely and effective treatments.

Quantum computing

Quantum computing represents the potential to change the way we view data storage, specifically in neurology. Unlike classical computers, which use bits to process information as binary 0s or 1s, quantum computers use qubits that can exist in multiple states simultaneously due to superposition. This allows quantum computers to process vast amounts of data at unprecedented speeds, making them exceptionally powerful for complex computations. Quantum computing could significantly enhance our ability to analyze large datasets, such as those generated from neuroimaging, genomics, and EHRs. The ability to process and analyze these massive datasets more efficiently can lead to more accurate models of brain function, disease progression, and treatment outcomes. For example, quantum algorithms could optimize machine learning models used for diagnosing neurological disorders, predicting disease trajectories, and personalizing treatment plans.

In summary, telemedicine and remote patient monitoring have emerged as transformative forces in neurological care, offering unprecedented access, convenience, and efficiency. From virtual consultations for stroke, neuromuscular disorders, and movement disorders to AI-driven early detection and prognostication in acute stroke management, these technologies are reshaping the landscape of neurological services. As we navigate the challenges posed by an aging population and a shortage of neurologists, the continued adoption and advancement of telemedicine hold immense promise in ensuring timely, equitable, and effective care for patients with neurological conditions worldwide.

Genetics and Omics: Driving Personalized Medicine in Neurology

The genetic and molecular insights gained from omics studies are informing the development of neurotechnological interventions, from brain-computer interfaces to neuroprosthetics (**Figure 3**). Despite the historical limitations imposed by the high costs of genetic analysis and the constrained ability to address neurologic disorders once identified, recent technological advancements in DNA sequencing and gene editing have propelled genetic analysis and gene therapy to the forefront of clinical neurology. These innovations promise significant improvements in patient care, emphasizing the critical role of genetics in understanding and managing neurologic diseases. The human genome's complexity, with its 3 billion nucleotides, of which less than 2% encode proteins, underlines the intricate relationship between genetic variations in both protein-coding genes and noncoding regulatory DNA and disease risk. Diseases can be monogenic, resulting from a single gene mutation, or polygenic, involving mutations across multiple genes. The advent of next-generation sequencing (NGS) has exponentially increased the speed, accuracy, and affordability of DNA sequencing, making it possible to use an individual's genome to guide their medical care. This leap in sequencing technology, alongside developments in gene editing, particularly CRISPR/Cas9, marks significant advancement toward correcting genetic mutations responsible for neurologic diseases.

The integration of genomic information from genome-wide association studies (GWAS) for predicting disease risk and aiding in the identification of patient populations for clinical trials, points toward a future where genetic screening plays a crucial role in early intervention strategies. As gene-based diagnostics and treatments become more accessible and refined, the potential for addressing a vast array of neurologic conditions grows, underscoring the importance of continued investment in basic science research to fuel the development of tomorrow's treatments.

Genetics in Predictive Analytics

Together, NGS and GWAS significantly enhance neurological predictive analytics by offering a comprehensive approach to understanding complex diseases. NGS provides detailed genetic screening and diagnosis, enabling precise prognostication, informed treatment planning, and accurate genetic counseling through genetic risk scores. It deepens our understanding of disease mechanisms by mapping phenotype/genotype correlations, paving the way for novel therapies and personalized medicine in neurology. GWAS, in turn, identifies genetic loci associated with various neurological conditions, illuminating their heritability, pathophysiology, and revealing potential therapeutic targets. Collectively, these technologies form a potent toolkit for elucidating the genetic foundations of neurological disorders, promising advancements in treatment and patient care [91–93].

In the past two decades, GWAS facilitated many discoveries, such as the identification of multiple

novel risk loci In neurodegenerative diseases like Alzheimer's Disease and Parkinson's Disease (CR1, BIN1 and PICALM for AD [94]; SNCA, MAPT for PD [95]) that elucidate roles in lipid-processing, the immune system, and synaptic-cell functioning pathways. Similarly, in Amyotrophic Lateral Sclerosis (ALS), GWAS findings have highlighted genes such as UNC13A, and the significance of the 9p21.2 region in both familial and sporadic forms. [96,97] Chronic conditions such as Multiple Sclerosis (MS) [98], Epilepsy [99], and Restless Legs Syndrome (RLS) [100] have benefited from GWAS revealing numerous loci, particularly highlighting the autoimmune nature of MS and the dopaminergic neurotransmission and iron dysregulation in RLS. Cerebrovascular disorders, such as Stroke [101] and Moyamoya Disease (MMD) [102], have revealed specific genetic risk factors through GWAS, including the identification of eight different loci causing neurological instability post-ischaemic stroke and the strong association of the RNF213 locus with MMD risk. These discoveries underscore the complexity of neurological diseases and the crucial role of genetic factors, paving the way for targeted therapies and improved diagnostic strategies.

Genetic insights are instrumental for predictive models that use algorithms and statistical techniques, including machine learning and neural networks, to identify patterns and predict future clinical outcomes from data. For example, in neurovascular conditions such as cerebral aneurysms [103] and arteriovenous malformations (AVMs) [104], predictive models have successfully forecasted risks of cerebral aneurysm rupture and outcomes following endovascular treatment of AVMs. These predictions are based on a combination of basic demographics, clinical information, and computational blood flow simulations processed through machine learning and image processing techniques.

Beyond DNA sequencing, other 'omics' have been transformative in various neurology traits. For instance, transcriptomics analysis, used to measure the expression levels of genes, provided significant insights across various diseases. In AD, it uncovered three molecular subtypes [105] and led to the development of a blood RNA test that distinguishes AD from other dementias before symptom onset [106,107], also highlighting the downregulation of *NeuroD6* as a potential biomarker [108]. For PD, it enabled patient stratification based on mitochondrial or lysosomal dysfunctions and assisted in selecting neuroprotective compounds [109]. In ALS, transcriptomics analysis facilitated the molecular classification into two distinct subtypes, SALS1 and SALS2, by analyzing deregulated genes and pathways in postmortem cortex transcriptomes [110,111]. Moreover, it revealed CNS dysregulation of over 300 biological processes in prion infections and suggested alternative pathways for astrocyte activation [112]. It also identified molecular heterogeneity in trigeminal ganglia sub-regions, aiding in the understanding of migraine and headache mechanisms through the analysis of

postmortem trigeminal ganglia [113]. Even though it was revolutionary at the time, bulk transcriptomics analysis has several disadvantages that have prompted the development and adoption of single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics technologies. One key limitation of bulk transcriptomics is its inability to capture cellular heterogeneity within complex tissues or cell populations, as it provides only an average expression profile from a bulk sample. This averaging mask the diversity of individual cell types and their unique transcriptional states, which are crucial for understanding biological processes and disease mechanisms. Additionally, bulk transcriptomics lacks spatial context, meaning it cannot pinpoint where in a tissue-specific genes are being expressed. scRNA-seq addresses these issues by profiling the transcriptomes of individual cells, revealing the cellular heterogeneity and enabling the identification of rare cell types and subpopulations. This detailed cellular landscape often yields valuable insights into disease progression, such as the discovery of key demyelinating subpopulations mediating early Alzheimer's disease (AD) progression [114]. These discoveries are made possible and reliable due to large scRNA-seq databases, which can be either self-generated or obtained from publicly available repositories and atlases. The past decade has witnessed the emergence of many such atlases, including the Allen Brain Atlas [115], making it easier for researchers to conduct scRNA-seq analysis, as self-sequencing of data may be time-consuming and costly. Spatial transcriptomics technologies go a step further by retaining the spatial context of gene expression, allowing researchers to map where in a tissue each gene is active. Together, scRNA-seq and spatial transcriptomics offer a more detailed and nuanced view of gene expression.

Selective neuronal vulnerability as a sub-field in neurology focuses on the molecular mechanisms underlying enhanced neuronal degeneration. This field highly benefited from single-cell technologies, where it linked tau accumulation to AD progression and depletion of specific excitatory neurons [116]. Additionally, these technologies enabled the identification of molecular features pruning degradation of dopaminergic neurons in PD [117]. Moreover, it facilitated the characterization of specific hippocampus and dorsolateral prefrontal cortex (DLPFC) neuronal subtypes, involved in many neuropsychiatric disorders such as schizophrenia and major depressive disorder (MDD) [118]. Another neurology sub-field highly benefiting from scRNA-seq based discoveries is neuroimmune dysfunction, which sheds light on the function of immune cells in neurodegenerative disease progression. For example, studies have identified disease-associated microglia (DAM) with unique gene expression profiles in AD models, and distinct microglial responses associated with different stages of neurodegeneration [119,120]. In MS, transcriptomic analyses have uncovered microglial subtypes with specific gene dysregulations, suggesting potential

therapeutic targets [121]. Furthermore, the adaptive immune response, involving T cells and B cells, has been implicated in the pathology of MS and PD, highlighting the influence of immune cells on neuronal degeneration [122,123]. Single-cell sequencing has also revealed key insights into glioma, showing how myeloid cell interactions within the tumor microenvironment drive disease progression and affect treatment outcomes [124]. Similarly, in COVID-19, it has identified changes in microglia and astrocytes gene expression, suggesting that inflammation and immune responses contribute to neurological symptoms, opening new paths for treatment [125]. Finally, single-cell technologies have also revolutionized the understanding of how different cell types within the CNS and tumors respond to treatments. In glioblastoma [126] and medulloblastoma [127], for instance, scRNA-seq has identified potential therapeutic targets based on the cells' developmental and inflammatory processes, demonstrating the potential for tailored treatments.

Despite significant advancements in the field, single-cell transcriptomics still faces challenges and limitations. These include technical hurdles in sample collection [128] and cell isolation from brain tissue [129,130], which impact data quality and reproducibility. Key future directions involve advancing single-cell multi-omics to integrate various data types with clinical information, enhancing the precision of spatial transcriptomics, and applying these technologies to brain organoids for deeper insights into brain function and pathology.

Neurotechnology: Advancing Diagnosis, Treatment, and Rehabilitation in Neurology

Neurotechnology refers to the integration of techniques and devices facilitating a direct interface between technical apparatuses and the nervous system (**Figure 4**). These technical components, including electrodes, computers, or advanced prostheses, serve the purpose of capturing signals from the brain and converting them into operational commands, or modulating brain activity through the application of electrical or optical stimuli. Ongoing research explores closed-loop interactions between systems for signal acquisition and stimulation (control circuits) [131].

Neurotechnology has its roots in the early exploration of brain electrical activity. Electrical currents of the brain were first described in 1875 by Richard Caton, who observed electroencephalography from exposed rabbits' and monkeys' brains. In 1924, German neurologist Hans Berger enhanced the measurement of human brain electrical activity through the scalp, recording and depicting it graphically on paper. This laid the foundation for modern EEG technology, which has become a cornerstone of non-invasive brain-computer interfaces (BCIs). EEG signals are

now commonly utilized in BCIs to facilitate bi-directional communication between the human brain and external devices. By monitoring various cortical regions, it is possible to extract signals across multiple frequency bands associated with distinct human behaviors, enabling the study of corresponding patterns. EEG-based BCIs have significantly advanced our understanding of cognitive activities and contributed to progress in computer science and engineering [132]. In EEG-based BCI applications, machine learning technologies typically fall into two major categories: classification and individual adaptive tasks. Deep learning, a subset of machine learning, employs deep neural networks to learn EEG patterns [133], featuring numerous neurons across multiple layers to capture cognitive-related features. The potential of BCIs is particularly evident in the field of robotics. EEG-based BCIs have demonstrated efficacy in communication with robots, with early applications including the control of wheelchairs through visual simulations or motor imagery [132]. These advancements pave the way for more sophisticated neurotechnological interventions in movement, language, and speech, as we'll explore in the following sections.

In summary, as neuroprosthetics involve devices that interact directly with the nervous system to restore or enhance neural functions and BCIs enable direct communication between the brain and external devices, they can bypass traditional pathways. They typically rely on electrodes that capture electrical signals from the brain or stimulate neural tissue. These electrodes can be non-invasive, placed on the scalp, or invasive, implanted directly into the brain. BCIs decode neural signals into commands that control prosthetic limbs, computers, or other devices, often using machine learning algorithms to interpret complex brain activity. There are few technical challenges such as ensuring long-term biocompatibility and stability to prevent immune responses and device degradation. The integration of neurotechnology into clinical practice requires extensive training for both patients and healthcare providers. Patients must learn to use and control neuroprosthetic devices effectively, which often involves cognitive and physical training. Healthcare providers need specialized knowledge to implant, configure, and maintain these devices, as well as to provide ongoing support and adjustments based on patient needs.

Aiding movement language and speech

One example is neurotechnological electrodes. These electrodes are capable of non-invasively capturing electrical fields generated by the active brain, typically facilitated by their placement on the surface of the head in the form of electrode caps. This method is deemed non-invasive as the electrodes do not penetrate bodily tissues. Notably, it finds application in patients afflicted with ALS,

particularly during the advanced, near-complete paralysis stages where it aids speech by synthesizing it in real-time directly from brain activity [134]. For instance, electrodes utilized for deep brain stimulation (DBS) are meticulously inserted by neurosurgeons into targeted brain regions. Through modulation of these targets, it becomes feasible to suppress or ameliorate certain symptoms associated with various brain disorders. For instance, DBS serves as a therapeutic option for patients grappling with Parkinson's Disease (PD) when conventional medication proves ineffective. While DBS does not offer a cure or halt the progression of neurodegenerative processes, it substantially alleviates hallmark symptoms such as tremors or rigidity, thereby significantly enhancing patient well-being and overall quality of life [131].

Neurological wearables

Another illustration within the realm of neurotechnology pertains to neurological wearables. A primary challenge concerning wearable sensors revolves around creating stretchable and skin-attachable electronic devices capable of seamlessly and inconspicuously monitoring human activity and vital signs without impeding or restricting the user's movement [135]. The initial breakthrough in implantable medical devices came with the development of a pacemaker for arrhythmia patients in 1958 [136]. Since this milestone, a range of pacemakers and implantable cerebellar stimulators have been developed and utilized [135].

In neurology, wearable devices are considered an evolving technology, used to track and monitor the patient's ambulatory for long periods. It can track vital signs and other types of data, creating from them a digital profile of the patient [137], even during their sleep. The collected data is expected to improve the diagnosis, assessment, and treatment of patients with various conditions. Out of the healthcare companies investing in the development of wearable devices, around 60% were founded after 2006, whereas the most veteran one was founded in 1993 [138]. Many wearable devices were developed to diagnose, monitor, and treat neurological disorders such as stroke, PD and epilepsy. In stroke, smartphones and smartwatches are primarily used to monitor parameters such as upper extremity activity, walking, and physical activity [139]. All of which may detect pulse and cardiac arrhythmia [140] that can cause subsequent transient ischemic attacks or ischemic strokes [141]. In PD, wearables devices in the form of sensors attached to the lower back may track cardinal motor symptoms such as postural sway, tremor and bradykinesia, quantity and duration of freezing and falling phases, sleeping distributions and also more cognitively advanced symptoms like dyskinesia [139]. In epilepsy, most wearables are wrist-worn sensors with accelerometers, which are used to identify seizures based on movement patterns that might be associated with tonic-clonic or

convulsive seizures [139].

One example of such a device is the Embrace smartwatch, which quantifies alterations in skin electric conductance that correspond to epileptic activity within the brain, and it can notify contacts or caregivers about the seizure activity it identified [142]. Other such devices include one that had electrodes attached to the biceps and detects tonic-clonic seizures and another that detects simple partial seizures [142].

An additional instance pertains to the utilization of wearables within the realm of sleep neurology. The neurological status of patients is notably influenced by both the quality and quantity of sleep. Wrist-worn actimetry sensors have been established as longstanding tools in sleep studies, enabling the monitoring of various physiological parameters associated with sleep [141]. These devices may be supplemented by cardiac monitoring or mattress-based devices, colloquially termed "nearables," which possess the capability to track respiratory movements [143]. Several newer devices actively intervene with the patient's sleep, helping them to get better sleep quality [141]. In all the mentioned wearables, AI technologies play a crucial role in its embedded architecture, as they enable the mass analysis and process of the detected data. However, efficient AI requires large amounts of training data, effective noise removal from detected features, and subsequent feature selection (i.e., focusing on important data characteristics for each type of evaluation). Furthermore, it involves distinguishing between similar activities and developing computationally efficient algorithms and hardware implementations. Nevertheless, there are significant technical challenges such as the need for energy-efficient designs to ensure long battery life, robust data privacy and security measures, and overcoming the devices limitations of real-time data processing. Addressing these challenges is essential for the successful deployment and widespread adoption of AI-enabled neurological wearables [144,145].

Albeit its ongoing popularity and its contribution to patient care, there are some current issues with wearables in the field of neurology. These mainly include a lack of high-quality data, absence of accepted evaluation standards, and limited implementation strategies: Many wearables lack robust efficacy data that would improve the care of abundant disabling neuropsychiatric conditions such as migraine and depression [141]. As of evaluation standards, even though the American Psychiatric Association has proposed in 2018 a framework for evaluating digital health tools [146], there is still no widely accepted standard [147]. Said lack of standards results in inconsistent evaluations and limits implementations. Aside of evaluation problems, the rapid development of wearables also outpaces the creation of validation protocols, resulting in a lag in adapting these tools to healthcare systems [141].

Robotics in neurological diseases

Researchers have discovered that robotic devices significantly enhance stroke rehabilitation by offering patients tailored, intensive, and repetitive training. These devices facilitate real-time feedback, enabling immediate correction of movement errors, thus fostering more efficient and effective motor learning. With the ability to provide targeted training, these robots not only enhance motor learning but also deliver objective performance and function measurements. Customizable to individual patient needs, these robotic systems can be programmed for specific training or therapeutic interventions, underscoring their versatility in rehabilitation [148]. Neural rehabilitation is an emerging field aiming to restore defective neurological circuits' functionality or enhance the remaining functionality of impaired ones. Its purpose is to enhance patient's independence and improve quality of life by relying on the principle of neuroplasticity [149,150], a subject that relies on the idea that central nervous systems (CNS) and peripheral nervous systems (PNS) can be retrained after injury in order to get an effective rehabilitation [151]. Another application is in pediatric neurosurgery, robot-assisted stereotactic biopsies for brainstem and thalamic lesions have proven effective, showcasing the potential of robotic procedures in enhancing surgical precision, and accuracy, and minimizing tissue damage. This approach has been particularly promising in pediatric neurosurgery, offering a method to improve outcomes while reducing the risk to surrounding healthy tissues [148].

Robotics is also making strides in the clinical assessment of neurological disorders and upper-limb therapy, indicating a broader application of this technology beyond traditional settings. Investigations into robot-assisted diagnosis and the use of robotic control through neural interfaces for individuals with tetraplegia highlight the innovative applications of robotics in neurology and intensive care.

Human-robot interaction (HRI) is an emerging field that integrates AI, robotics, and social sciences to facilitate interaction and communication between humans and robots. It has various applications in medicine, and also specifically in neurorehabilitation [152,153]. When utilizing robots, numerous considerations must be taken into account, including safety, learning by demonstration, imitation learning, cognition and reasoning, perception, and more [154]. Typically, AI algorithms and systems are employed to address these issues, thereby enhancing the overall interaction and experience for patients. Owing to the presence of multiple representations within an environment, there is often an abundance of multimodal data, such as visual, audio, infrared, and ultrasound inputs. These inputs are utilized by AI algorithms capable of conducting tasks such as object classification, prediction, and task planning [155].

Neuroprosthetics

Neuroprosthetics is an evolving field that combines neuroscience, engineering, and medicine to develop devices that can restore or enhance neural function. These devices, known as neuroprostheses, interact directly with the nervous tissue, usually to bridge the gap between lost function and the brain's control over the body. Over the past 25 years, several key advancements have propelled the field of neuroprosthetics forward. Notable example of these advancements is BCIs, which have emerged as a promising avenue for restoring communication and control in patients with severe motor impairments. Notable achievements include the development of high-performance BCIs that enable users to control prosthetic limbs with near-natural dexterity and speed. One example of such achievement is a description of two patients with spinal cord injury who were able to regain their grasp function through neuroprosthesis, by using an asynchronous BCI, allowing them to complete a grasp-and-release test of the paperweight multiple times [156]. Another example is advancements in sensory restoration. Neuroprosthetics has made significant progress in restoring sensory function, particularly in the realm of hearing and vision. Cochlear implants, which aid more than half a million severely-to-profoundly hearing-impaired people worldwide [157], electrically stimulate the auditory nerve to restore hearing, have become increasingly sophisticated, offering improved sound quality and speech recognition. Recently, a demonstration of a new development in the cochlear implants field was presented, allowing better pitch perception for the users by using haptic stimulation on the forearm [157]. Similarly, retinal implants and optogenetic approaches have shown promise in restoring visual perception in individuals with blindness, as can be seen from the launching of two electrical retinal prostheses in the last two decades, as well as preclinical and early clinical trials of gene therapies in the field of optogenetics [158].

Neuroprosthetic devices have also been developed to stimulate the spinal cord, offering new treatment options for individuals with spinal cord injuries or neurological disorders. These devices can modulate neural activity in the spinal cord, leading to improved motor function, reduced spasticity, and enhanced sensory feedback. Recent studies have demonstrated the potential of spinal cord stimulation to restore voluntary movement in patients with paraplegia. Another demonstration is of FES electrodes that help patients with improper trunk stabilization due to SCI by stimulating lumbar erector spinae among other muscles, improving their posture and forward reach and easing their transfers [159,160]. Furthermore, epidural spinal cord stimulation has been proven to activate central pattern generator (CPG) for locomotion, thus improving walking in patients with incomplete SCI [161].

Neuroprosthetics have led to the development of closed-loop systems that can sense and respond to neural activity in real-time. These systems incorporate feedback mechanisms that allow the device to adapt its stimulation parameters based on the user's needs and intentions. Closed-loop neuroprosthetics have shown promise in applications such as tremor suppression in Parkinson's disease and seizure detection and intervention in epilepsy. A neurotechnology company created a closed-loop stimulation device that can detect and prevent seizures from four channels [162], by comparing pre-seizure parameters to pre-defined thresholds, by both cortical and deep-brain stimulation. It also reduced sudden unexpected death in epilepsy significantly [163]. Another company developed a closed-loop device for PD treatment, that can record focal deep-brain potentials and accordingly adjust the stimulation amplitude and frequency [164].

Finally, neuroprosthetic devices have become increasingly miniaturized and wireless, improving their implantability and reducing the risk of complications. Wireless power transfer and data communication have enabled the development of fully implantable systems that can operate without the need for external hardware. These advances have greatly enhanced the practicality and acceptability of neuroprosthetic devices for long-term use. One example of miniaturized neuroprosthetics is cochlear implants, which use small electrode with small diameter wires of 20 μm [165] and an electrode array that is considered one of the longest is only 31.5 mm [166]. Another example of a miniaturized and wireless device is an endovascular, wireless and battery-free millimetric implant that can stimulate specific peripheral nerves that are difficult to reach surgically [167].

Despite these advancements, challenges remain in the field of neuroprosthetics. These include ensuring the long-term stability and biocompatibility of implanted devices, optimizing the specificity and resolution of neural interfaces, and developing more intuitive control strategies for users. Additionally, translating neuroprosthetic technologies from research settings to clinical practice requires rigorous testing, regulatory approval, and consideration of ethical and social implications.

Looking ahead, the field of neuroprosthetics holds immense promise for improving the lives of individuals with neurological disorders or injuries. Ongoing research aims to further enhance the functionality and usability of neuroprosthetic devices, incorporating advancements in materials science, machine learning, and neuroscience. As these technologies continue to evolve, they have the potential to revolutionize the way we approach neurological rehabilitation and restoration of function.

Advancements in Neuroimaging: Transforming Neurosurgery, Neuro-oncology and Stroke

Care

As we look forward to breakthroughs in neuroprosthetics, advancements in neuroimaging are equally revolutionizing the field of neurological diagnostics and treatments. The advent of new imaging techniques like CT (Computed Tomography), NMR (Nuclear Magnetic Resonance), PET (Positron Emission Tomography), and ultrasonic scanning has revolutionized our understanding of the nervous system in both its healthy state and when affected by disease (**Figure 4**). These advancements have provided unprecedented clarity and detail in imaging, greatly enhancing our diagnostic capabilities.

Neuro-oncology and neurosurgery

Innovations in neuroimaging have been pivotal in enhancing patient care, significantly reducing morbidity and mortality rates among neurosurgical patients [168]. The improvement in brain MRI for anatomical mapping has led to rapid growth and progress. This enhancement is important for diagnosing and treating oncological diseases of the nervous system, which include a variety of tumors such as meningiomas. Among the most prevalent primary brain tumors in adults are cerebral gliomas, with an incidence rate of 5–6 per 100,000 person-years [169]. At the point of initial diagnosis, the challenge of distinguishing brain tumors from benign lesions is challenging due to their similar appearances on MRI scans. Contrast-enhanced MRI, favored for its superior soft-tissue resolution and accessibility, serves as the primary method for such differentiation. Typically, brain tumor diagnoses rely on conventional MRI techniques, including T1-weighted and T2-weighted sequences. However, these standard imaging approaches sometimes struggle to distinguish between tumor changes due to disease progression and non-specific, treatment-related alterations, especially after therapeutic interventions. PET scanning, employing various radioactive tracers to target distinct metabolic and molecular processes, offers more data that enhances specificity, especially in clinically ambiguous cases. Radiolabelled amino acids in PET scanning become essential in neurodiagnostics, with the Response Assessment in Neuro-Oncology (RANO) working group recommending its use alongside MRI for comprehensive brain tumor management [171]. Meanwhile, advanced MRI techniques like perfusion-weighted imaging (PWI) [172], diffusion-weighted imaging (DWI) [173], and proton magnetic resonance spectroscopic imaging (MRSI) [173] continue to be evaluated clinically for their potential to provide critical physiological or biochemical insights beyond standard MRI capabilities. The evolution of modern neurosurgery and radiology demonstrates the impact of radiological advancements on neurosurgical practices. The pace of these developments is so rapid that newer neurosurgical residents might be unfamiliar with older procedures like pneumoencephalography or the challenges of distinguishing between neurosurgical

pathologies before the advent of CT. Moreover, such progress has supported the execution of high-quality clinical trials, improving evidence-based neurosurgical practice.

Stroke medicine

Stroke is one of the leading causes of death in older ages and time to treatment is crucial. Over the recent decades, ischemic stroke medicine has evolved with new technological innovations, specifically with the advent of AI and the below few critical examples are just the tip of the iceberg. Multiple AI-based models are able to detect and segment core infarct, detect large vessel occlusion (LVO), calculate ASPECTS score, and more [175]. One example is a study from 2011 a computer-automated detection (CAD) scheme utilizing a circular adaptive region of interest (CAROI) method was developed and implemented on noncontrast head CT scans to identify subtle changes in attenuation indicative of ischemic stroke [176]. Their findings indicated that CAD significantly enhanced the detection of strokes for emergency physicians and radiology residents. [176] In another study, researchers demonstrated the efficacy of an artificial neural network in distinguishing acute strokes from stroke mimics within 4.5 hours of symptom onset, with a mean sensitivity of 80.0% and specificity of 86.2% [177]. In the domain of automatic lesion segmentation, a recent study employed an ensemble of two Convolutional Neural Networks (CNNs) to effectively segment Diffusion-Weighted Imaging (DWI) lesions, irrespective of their size, while simultaneously mitigating false positives, achieving a Dice score of 0.61 for small lesions and 0.83 for large lesions [178]. In detecting large vessel occlusions, a Support Vector Machine (SVM) algorithm demonstrated high sensitivity (97.5%) in identifying the MCA dot sign on Non-contrast CT scans in acute stroke patients [179]. A commercial software, based on CNN, achieved an accuracy of 86% in detecting proximal (LVO), with a sensitivity of 90.1% and specificity of 82.5% [180]. In ASPECTS grading, a commercial software platform offering automated ASPECTS scoring demonstrated comparable performance to neuroradiologists in scoring ASPECTS on non-contrast CT scans in patients with acute stroke ($p < .003$) [181]. In stroke prognosis, a study found that a generalized linear model combining DWI and perfusion-weighted imaging MR outperformed individual modalities in predicting tissue outcomes [182], and another study showed that a CNN trained on MRP source images achieved an AUC of 0.871 in predicting final infarct volume [183].

Neurodegenerative diseases

The significance of biomarkers in comprehending and diagnosing neurodegenerative diseases is growing. The use of imaging biomarkers for the live examination of these disorders has seen a significant rise in recent decades, offering enhanced diagnostic capabilities and deeper insights into

disease mechanisms.

Neurodegenerative diseases, notably Alzheimer's disease (AD), are understood to commence years before the manifestation of symptoms. Research, particularly on familial AD, outlines a sequence of pathological events beginning with the buildup of amyloid-beta ($A\beta$), detectable via positron emission tomography (PET) imaging and cerebrospinal fluid analysis, culminating in cognitive deficits and dementia. These processes not only occur in a specific sequence but also overlap over time, offering insights into the disease's progression. The National Institute on Aging and Alzheimer's Association (NIA-AA) has established a research framework for AD diagnosis, utilizing the AT(N) scale to categorize $A\beta$, tau, and neurodegeneration markers. These markers, identifiable through imaging biomarkers in vivo, enhance the sensitivity and specificity of AD diagnostics, underscoring the vital role of advanced imaging techniques in the early detection and understanding of neurodegenerative diseases. Neuroimaging has become integral to diagnosing suspected neurodegenerative diseases, employing various magnetic resonance imaging (MRI) techniques, and developing novel PET ligands. These tools provide objective measures for detecting and monitoring disease presence and progression, aiding in patient care, and facilitating clinical trial recruitment and treatment efficacy evaluation. The cross-disciplinary approach, incorporating imaging biomarkers, is crucial for diagnosing and comprehending neurodegenerative disorders, emphasizing the expanding utility of neuroimaging in medical research and patient management. [184] Amyloid-beta ($A\beta$) PET imaging has transformed the diagnostic landscape for AD, allowing for the in vivo quantification of $A\beta$ plaques, a key AD biomarker. The development of $A\beta$ -specific PET tracers, such as Pittsburgh compound B (PiB) and subsequent F-18-labelled tracers, has facilitated this advancement [185]. Similarly, tau-specific PET tracers have opened new avenues for diagnosis, prognosis, and clinical trial outcomes in AD, correlating tau pathology with cognitive symptoms and deterioration [186]. The portfolio of PET ligands for identifying biomarkers of neurodegeneration has grown considerably, with some advancing to clinical use and others offering new insights into these conditions. MRI techniques continue to aid diagnosis and enhance our understanding of neurodegenerative diseases, with structural MRI being the most accessible imaging tool. FDG PET, despite its limitations, remains a valuable tool for investigating neuronal injury in dementia [187], illustrating the complex nature of neuroimaging in understanding and treating neurodegenerative diseases.

Few studies also use machine learning aiding diagnosis. For example, an innovative CAD system was developed to diagnose AD from MRI images, based on aging brains and machine learning, and to identify the AD-related regions. [188] The experiments demonstrated that the proposed method

can predict AD subjects with a competitive accuracy of 92.36%, comparable to existing methods. In another study, the researchers trained a deep learning algorithm based on CNN to predict a diagnosis of AD or mild cognitive impairment, based on F-FDG-PET imaging [189]. The algorithm achieved an impressive Area Under the Receiver Operating Characteristic (AUC-ROC) curve of 0.98 when predicting the final clinical diagnosis of AD in an independent test set. It demonstrated 82% specificity at 100% sensitivity, with predictions made an average of 75.8 months prior to the final diagnosis. Notably, the algorithm's performance surpassed that of human readers, with a sensitivity of 57% and specificity of 91%. Saliency map analysis revealed attention to known areas of interest, highlighting the entire brain's importance in the diagnostic process. [189] Another example is Parkinson's disease (PD), a common neurodegenerative disease where early detection is highly important to improve patient's quality of life [190]. In recent years, remarkable progress has been made in employing advanced computational methods in neuroimaging, providing a valuable tool set for the medical imaging research community to extract pertinent features. These methodologies have been instrumental in developing sophisticated diagnostic approaches for PD [190]. In one study neural activity and functional connectivity within the olfactory brain network were investigated [191]. Through the application of Independent Component Analysis (ICA) and the Generalized Linear Model (GLM), discernible differences between PD patients and healthy controls were identified, with ICA demonstrating superior performance compared to GLM. Similarly, a predictive model utilizing fMRI datasets for PD diagnosis through multiclass subject classification was devised [192]. Feature reduction and selection were achieved using Principal Component Analysis (PCA) and the Fisher Discriminant Ratio, while the classification task was carried out using the Least-Squares Support Vector Machine. Notably, these classifiers exhibited impressive accuracy levels of up to 87.89% and a precision of 82.54%. In another study, resting-state fMRI datasets were employed, leveraging an SVM classifier to effectively distinguish 19 PD patients from 18 healthy controls [193]. In a study aimed to build a model based on Grey's cerebellum changes, an SVM classifier used data of cerebellar structural changes derived from Voxel-based Morphometry (VBM) for PD detection with an accuracy of more than 95% [194]. Researchers also reported that they were able to detect and differentiate successfully PD patients from healthy ones, by associating different facial expressions and brain activity on fMRI [195].

In conclusion, the field of medical imaging has witnessed remarkable progress, evolving from the inception of X-rays to the advent of fMRI and other cutting-edge technologies. This trajectory of innovation, coupled with the emergence of AI technologies, has paved the way for groundbreaking applications in the realm of neurological disorders, significantly enhancing our understanding of

various neurological conditions.

Summary

The integration of AI with new medical technological advancements has ushered in a transformative era for neurology, reshaping diagnostic, therapeutic, and research landscapes. With the advent of EHR systems and the widespread adoption of telemedicine, neurologists now have unparalleled access to patient data and the ability to deliver care remotely. This shift streamlines clinical workflows and enhances patient care by enabling precise and timely interventions. As most neurological conditions are chronic and require monitoring, this advancement allows for scaling in treatment. Furthermore, the burgeoning field of predictive modeling, powered by vast databases of EHRs, leverages AI to forecast clinical outcomes, offering personalized treatment strategies.

The paradigm shift from traditional physical examinations to reliance on technological data has significantly impacted patient triage and clinical management. Innovations such as advanced imaging technologies, revolutionized neurological diagnostics, providing deep insights into the brain's anatomy and function. Stroke prevalence led to the dire need for rehabilitation in neurology, new wearable devices and robotics in rehabilitation have further expanded the horizons of patient care, offering targeted therapy that adapts to the dynamic needs of individuals and saves expensive hospital visits. These technological advancements highlight the evolving approach to neurology, emphasizing the importance of integrating cutting-edge tools for improved diagnosis, treatment, and patient outcomes. AI models that analyze brain imaging to detect strokes, coupled with predictive models for conditions like ALS and Alzheimer's disease, demonstrate the potential of machine learning to improve patient care and bring to fruition personalized medicine in neurology. The collaboration between neurology and AI technologies paves the way for breakthroughs in understanding and treating neurological disorders, marking a significant leap toward advancing neuroscientific research.

Limitations exist for all these transforming ideas exist in all areas with few examples in fields of advanced imaging technologies (fMRI, PET, and CT) with cost, accessibility, resolution limits. Another example is AI algorithms and potential biases or hallucinations, data requirements, and the challenges in integrating into clinical practice or ensuring patient privacy. In genomics the issue of ethical concerns, off-target effects, and the high cost of these technologies and more.

In summary, the intersection of neurology with emerging technologies has fundamentally changed the landscape of neurological practice. From enhancing diagnostic accuracy and streamlining patient care to personalizing treatment strategies, the entire neurology field stands at the forefront of this

revolution. The integration of AI, advanced imaging, and telemedicine underscores its dynamic evolution, driven by the pursuit of excellence in patient care and neuroscientific discovery.

Reference

1. Steinmetz, J. D. *et al.* Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Neurol.* **23**, 344–381 (2024).
2. Ding, C. *et al.* Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990-2019. *Front. Public Health* **10**, 952161 (2022).
3. Muhrer, J. C. The importance of the history and physical in diagnosis. *Nurse Pract.* **39**, 30–35 (2014).
4. Salenius, S. A. *et al.* An electronic medical record system with direct data-entry and research capabilities. *Int. J. Radiat. Oncol.* **24**, 369–376 (1992).
5. Weed, L. L. The problem oriented record as a basic tool in medical education, patient care and clinical research. *Ann. Clin. Res.* **3**, 131–134 (1971).
6. McDonald, C. J. & Tierney, W. M. The Medical Gopher--a microcomputer system to help find, organize and decide about patient data. *West. J. Med.* **145**, 823–829 (1986).
7. Rodnick, J. E. Should the complete medical record be computerized in family practice? An opposing view. *J. Fam. Pract.* **30**, 460–464 (1990).
8. American Health Information Management Association. Position statement. Issue: Healthcare reform. *J. AHIMA* **63**, suppl 2 p. (1992).
9. Widman, L. E. & Freeman, G. L. A-to-D conversion from paper records with a desktop scanner and a microcomputer. *Comput. Biomed. Res. Int. J.* **22**, 393–404 (1989).
10. Litt, H. I. & Loonsk, J. W. Digital patient records and the medical desktop: an integrated physician workstation for medical informatics training. *Proc. Symp. Comput. Appl. Med. Care* 555–559 (1992).
11. Dolin, R. H. Outcome analysis: considerations for an electronic health record. *MD Comput. Comput. Med. Pract.* **14**, 50–56 (1997).
12. Ben-Assuli, O., Shabtai, I. & Leshno, M. Using electronic health record systems to optimize admission decisions: the Creatinine case study. *Health Informatics J.* **21**, 73–88 (2015).
13. Albagmi, S. The effectiveness of EMR implementation regarding reducing documentation errors and waiting time for patients in outpatient clinics: a systematic review. *F1000Research* **10**, 514 (2021).
14. McCarthy, L. H., Longhurst, C. A. & Hahn, J. S. Special requirements for electronic medical

- records in neurology. *Neurol. Clin. Pract.* **5**, 67–73 (2015).
15. Agosta, F. *et al.* Survival prediction models in motor neuron disease. *Eur. J. Neurol.* **26**, 1143–1152 (2019).
 16. Galovic, M. *et al.* Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study. *Lancet Neurol.* **17**, 143–152 (2018).
 17. Triplett, J. D. *et al.* Diagnostic modelling and therapeutic monitoring of immune-mediated necrotizing myopathy: role of electrical myotonia. *Brain Commun.* **2**, fcaa191 (2020).
 18. Zweifel, C. *et al.* Continuous monitoring of cerebrovascular pressure reactivity in patients with head injury. *Neurosurg. Focus* **25**, E2 (2008).
 19. Timofeev, I. *et al.* Ventriculostomy for control of raised ICP in acute traumatic brain injury. *Acta Neurochir. Suppl.* **102**, 99–104 (2008).
 20. Zhang, X. *et al.* Invasive and noninvasive means of measuring intracranial pressure: a review. *Physiol. Meas.* **38**, R143–R182 (2017).
 21. Goodman, J. C. & Robertson, C. S. Microdialysis: is it ready for prime time? *Curr. Opin. Crit. Care* **15**, 110–117 (2009).
 22. Okonkwo, D. O. *et al.* Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase-II: A Phase II Randomized Trial. *Crit. Care Med.* **45**, 1907–1914 (2017).
 23. Fandino, J., Stocker, R., Prokop, S., Trentz, O. & Imhof, H. G. Cerebral oxygenation and systemic trauma related factors determining neurological outcome after brain injury. *J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas.* **7**, 226–233 (2000).
 24. Vigué, B. *et al.* Early SjvO₂ monitoring in patients with severe brain trauma. *Intensive Care Med.* **25**, 445–451 (1999).
 25. Rivera-Lara, L. *et al.* Predictors of Outcome With Cerebral Autoregulation Monitoring: A Systematic Review and Meta-Analysis. *Crit. Care Med.* **45**, 695–704 (2017).
 26. Munir, K., De Ramón-Fernández, A., Iqbal, S. & Javaid, N. Neuroscience patient identification using big data and fuzzy logic—An Alzheimer’s disease case study. *Expert Syst. Appl.* **136**, 410–425 (2019).
 27. Eshaghi, A. *et al.* Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. *Nat. Commun.* **12**, 2078 (2021).
 28. Peter, I. *et al.* Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. *JAMA Neurol.* **75**, 939 (2018).
 29. Korean Ministry of Health and Welfare. Introducing a pilot system for electronic medical records of nationally certified hospitals. <https://www.korea.kr/news/policyNewsView.do?newsId=148879804> (2020).
 30. Korea Health Information Service. Standardization of hospital/clinic electric medical record

- (EMR). <https://www.k-his.or.kr/menu.es?mid=a20201020000> (2021).
31. Chen, S. *et al.* How Big Data and High-performance Computing Drive Brain Science. *Genomics Proteomics Bioinformatics* **17**, 381–392 (2019).
 32. The impact of the NIH BRAIN Initiative. *Nat. Methods* **15**, 839 (2018).
 33. Mahfoud, T. Visions of unification and integration: Building brains and communities in the European Human Brain Project. *New Media Soc.* **23**, 322–343 (2021).
 34. Okano, H. *et al.* Brain/MINDS: A Japanese National Brain Project for Marmoset Neuroscience. *Neuron* **92**, 582–590 (2016).
 35. Auger, S. D., Jacobs, B. M., Dobson, R., Marshall, C. R. & Noyce, A. J. Big data, machine learning and artificial intelligence: a neurologist's guide. *Pract. Neurol.* **21**, 4–11 (2020).
 36. Mueller, S. G. *et al.* The Alzheimer's Disease Neuroimaging Initiative. *Neuroimaging Clin. N. Am.* **15**, 869–877 (2005).
 37. Weiner, M. W. *et al.* The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. *Alzheimers Dement.* **6**, 202 (2010).
 38. Weiner, M. W. & Veitch, D. P. Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative. *Alzheimers Dement.* **11**, 730–733 (2015).
 39. Thompson, P. M. *et al.* The Enhancing NEUROIMAGING Genetics through Meta-Analysis Consortium: 10 Years of Global Collaborations in Human Brain Mapping. *Hum. Brain Mapp.* **43**, 15–22 (2022).
 40. the Alzheimer's Disease Neuroimaging Initiative (ADNI) *et al.* Identification of common variants associated with human hippocampal and intracranial volumes. *Nat. Genet.* **44**, 552–561 (2012).
 41. Hibar, D. P. *et al.* Novel genetic loci associated with hippocampal volume. *Nat. Commun.* **8**, 13624 (2017).
 42. Bearden, C. E. & Thompson, P. M. Emerging Global Initiatives in Neurogenetics: The Enhancing Neuroimaging Genetics through Meta-analysis (ENIGMA) Consortium. *Neuron* **94**, 232–236 (2017).
 43. for the ENIGMA-Major Depressive Disorder Working Group *et al.* Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. *Mol. Psychiatry* **22**, 900–909 (2017).
 44. for the ENIGMA Bipolar Disorder Working Group *et al.* Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. *Mol. Psychiatry* **23**, 932–942 (2018).
 45. Mitelpunkt, A. *et al.* Novel Alzheimer's disease subtypes identified using a data and knowledge driven strategy. *Sci. Rep.* **10**, 1327 (2020).

46. Xia, M. *et al.* Connectome gradient dysfunction in major depression and its association with gene expression profiles and treatment outcomes. *Mol. Psychiatry* **27**, 1384–1393 (2022).
47. Drysdale, A. T. *et al.* Resting-state connectivity biomarkers define neurophysiological subtypes of depression. *Nat. Med.* **23**, 28–38 (2017).
48. Wu, W. *et al.* An electroencephalographic signature predicts antidepressant response in major depression. *Nat. Biotechnol.* **38**, 439–447 (2020).
49. Barbanti, P. *et al.* The first report of the Italian Migraine Registry (I-GRAINE). *Neurol. Sci.* **43**, 5725–5728 (2022).
50. Burton, A. Smartphones versus Parkinson's disease: i-PROGNOSIS. *Lancet Neurol.* **19**, 385–386 (2020).
51. Cao, Z. A review of artificial intelligence for EEG-based brain–computer interfaces and applications. *Brain Sci. Adv.* **6**, 162–170 (2020).
52. Sree Shankar, S. & Rai, R. Human factors study on the usage of BCI headset for 3D CAD modeling. *Comput.-Aided Des.* **54**, 51–55 (2014).
53. LeCun Y, Ranzato M. Deep learning tutorial. In *Tutorials in International Conference on Machine Learning (ICML13)*, Atlanta, USA, 2013.
54. Vgontzas, A. & Renthal, W. Predicting erenumab adverse events with single-cell genomics. *Lancet Lond. Engl.* **396**, 95–96 (2020).
55. Hatcher-Martin, J. M. *et al.* Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology update. *Neurology* **94**, 30–38 (2020).
56. Algahtani, H. A. & Shirah, B. H. Rapid implementation of telemedicine in Neurology during the COVID-19 pandemic: Challenges in King Abdulaziz Medical City-Jeddah. *Neurosci. Riyadh Saudi Arab.* **27**, 4–9 (2022).
57. Laghari, F. J. & Hammer, M. D. Telestroke Imaging: A Review. *J. Neuroimaging* **27**, 16–22 (2017).
58. Mikulik, R. *et al.* Telemedicine-guided carotid and transcranial ultrasound: a pilot feasibility study. *Stroke* **37**, 229–230 (2006).
59. Hatcher-Martin, J. M. *et al.* Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology update. *Neurology* **94**, 30–38 (2020).
60. Reider-Demer, M., Raja, P., Martin, N., Schwinger, M. & Babayan, D. Prospective and retrospective study of videoconference telemedicine follow-up after elective neurosurgery: results of a pilot program. *Neurosurg. Rev.* **41**, 497–501 (2018).
61. Fidelix, E. C., Santana, G. C., Barros, D. M. da S. & Dourado Junior, M. E. T. Telehealth for amyotrophic lateral sclerosis in a multidisciplinary service in a Brazilian reference center. *Arq. Neuropsiquiatr.* **81**, 469–474 (2023).
62. Vargas, B. B. *et al.* Feasibility and accuracy of teleconcussion for acute evaluation of

- suspected concussion. *Neurology* **88**, 1580–1583 (2017).
63. Marshall, K. R. *et al.* Mild traumatic brain injury screening, diagnosis, and treatment. *Mil. Med.* **177**, 67–75 (2012).
 64. Yi, J. S., Pittman, C. A., Price, C. L., Nieman, C. L. & Oh, E. S. Telemedicine and Dementia Care: A Systematic Review of Barriers and Facilitators. *J. Am. Med. Dir. Assoc.* **22**, 1396–1402.e18 (2021).
 65. Patel, A. D. *et al.* Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 update. *Neurology* **91**, 829–836 (2018).
 66. Kissani, N. *et al.* Telemedicine in epilepsy: How can we improve care, teaching, and awareness? *Epilepsy Behav.* **103**, 106854 (2020).
 67. Qubty, W., Patniyot, I. & Gelfand, A. Telemedicine in a pediatric headache clinic: A prospective survey. *Neurology* **90**, e1702–e1705 (2018).
 68. Noutsios, C. D., Boisvert-Plante, V., Perez, J., Hudon, J. & Ingelmo, P. Telemedicine Applications for the Evaluation of Patients with Non-Acute Headache: A Narrative Review. *J. Pain Res.* **14**, 1533–1542 (2021).
 69. Müller, K. I., Alstadhaug, K. B. & Bekkelund, S. I. Telemedicine in the management of non-acute headaches: A prospective, open-labelled non-inferiority, randomised clinical trial. *Cephalalgia* **37**, 855–863 (2017).
 70. Ben-Pazi, H. *et al.* The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach. *Curr. Neurol. Neurosci. Rep.* **18**, 26 (2018).
 71. Stillerova, T., Liddle, J., Gustafsson, L., Lamont, R. & Silburn, P. Could everyday technology improve access to assessments? A pilot study on the feasibility of screening cognition in people with Parkinson's disease using the Montreal Cognitive Assessment via Internet videoconferencing. *Aust. Occup. Ther. J.* **63**, 373–380 (2016).
 72. Houston, E. *et al.* Telemedicine in Neurology: A Scoping Review of Key Outcomes in Movement Disorders. *Telemed. E-Health* **28**, 295–308 (2022).
 73. Yeroushalmi, S., Maloni, H., Costello, K. & Wallin, M. T. Telemedicine and multiple sclerosis: A comprehensive literature review. *J. Telemed. Telecare* **26**, 400–413 (2020).
 74. Sharma, S., Rawal, R. & Shah, D. Addressing the challenges of AI-based telemedicine: Best practices and lessons learned. *J. Educ. Health Promot.* **12**, 338 (2023).
 75. Spina, E. *et al.* How to manage with telemedicine people with neuromuscular diseases? *Neurol. Sci.* **42**, 3553–3559 (2021).
 76. Yamin, M. A. Y. & Alyoubi, B. A. Adoption of telemedicine applications among Saudi citizens during COVID-19 pandemic: An alternative health delivery system. *J. Infect. Public Health* **13**, 1845–1855 (2020).
 77. Giansanti, D., Morone, G., Loreti, A., Germanotta, M. & Aprile, I. A Narrative Review of the Launch and the Deployment of Telemedicine in Italy during the COVID-19 Pandemic.

Healthcare **10**, 415 (2022).

78. Tsao, C. W. *et al.* Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. *Circulation* **147**, e93–e621 (2023).
79. Donkor, E. S. Stroke in the 21st Century: A Snapshot of the Burden, Epidemiology, and Quality of Life. *Stroke Res. Treat.* **2018**, 3238165 (2018).
80. Goyal, M. *et al.* Analysis of Workflow and Time to Treatment and the Effects on Outcome in Endovascular Treatment of Acute Ischemic Stroke: Results from the SWIFT PRIME Randomized Controlled Trial. *Radiology* **279**, 888–897 (2016).
81. Sheth, S. A. *et al.* Time to endovascular reperfusion and degree of disability in acute stroke. *Ann. Neurol.* **78**, 584–593 (2015).
82. Chatterjee, A., Somayaji, N. R. & Kabakis, I. M. Abstract WMP16: Artificial Intelligence Detection of Cerebrovascular Large Vessel Occlusion - Nine Month, 650 Patient Evaluation of the Diagnostic Accuracy and Performance of the Viz.ai LVO Algorithm. *Stroke* **50**, AWMP16–AWMP16.
83. Barreira, C. M. *et al.* Abstract WP61: Automated Large Artery Occlusion Detection IN Stroke Imaging - ALADIN Study. *Stroke* **49**, (2018).
84. Hosny, A., Parmar, C., Quackenbush, J., Schwartz, L. H. & Aerts, H. J. W. L. Artificial intelligence in radiology. *Nat. Rev. Cancer* **18**, 500–510 (2018).
85. Lisowska, A. *et al.* Context-Aware Convolutional Neural Networks for Stroke Sign Detection in Non-contrast CT Scans. in *Medical Image Understanding and Analysis* (eds. Valdés Hernández, M. & González-Castro, V.) vol. 723 494–505 (Springer International Publishing, Cham, 2017).
86. Nagel, S. *et al.* Simplified selection criteria for patients with longer or unknown time to treatment predict good outcome after mechanical thrombectomy. *J. Neurointerventional Surg.* **11**, 559–562 (2019).
87. Nagel, S. *et al.* Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database. *Stroke* **49**, 1407–1411 (2018).
88. Chen, L., Bentley, P. & Rueckert, D. Fully automatic acute ischemic lesion segmentation in DWI using convolutional neural networks. *NeuroImage Clin.* **15**, 633–643 (2017).
89. Guerrero, R. *et al.* White matter hyperintensity and stroke lesion segmentation and differentiation using convolutional neural networks. *NeuroImage Clin.* **17**, 918–934 (2018).
90. Orrù, G., Pettersson-Yeo, W., Marquand, A. F., Sartori, G. & Mechelli, A. Using Support Vector Machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. *Neurosci. Biobehav. Rev.* **36**, 1140–1152 (2012).
91. Asadi, H., Dowling, R., Yan, B. & Mitchell, P. Machine Learning for Outcome Prediction of Acute Ischemic Stroke Post Intra-Arterial Therapy. *PLoS ONE* **9**, e88225 (2014).

92. Bentley, P. *et al.* Prediction of stroke thrombolysis outcome using CT brain machine learning. *NeuroImage Clin.* **4**, 635–640 (2014).
93. Tian, X. *et al.* Expanding genotype/phenotype of neuromuscular diseases by comprehensive target capture/NGS. *Neurol. Genet.* **1**, e14 (2015).
94. Black, M., Wang, W. & Wang, W. Ischemic Stroke: From Next Generation Sequencing and GWAS to Community Genomics? *Omics J. Integr. Biol.* **19**, 451–460 (2015).
95. Jiang, T., Tan, M.-S., Tan, L. & Yu, J.-T. Application of next-generation sequencing technologies in Neurology. *Ann. Transl. Med.* **2**, 125 (2014).
96. Marioni, R. E. *et al.* GWAS on family history of Alzheimer's disease. *Transl. Psychiatry* **8**, 1–7 (2018).
97. Fernández-Santiago, R. & Sharma, M. What have we learned from genome-wide association studies (GWAS) in Parkinson's disease? *Ageing Res. Rev.* **79**, 101648 (2022).
98. van Rheenen, W. *et al.* Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nat. Genet.* **48**, 1043–1048 (2016).
99. van Rheenen, W. *et al.* Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. *Nat. Genet.* **53**, 1636–1648 (2021).
100. International Multiple Sclerosis Genetics Consortium. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. *Am. J. Hum. Genet.* **92**, 854–865 (2013).
101. GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture | Nature Genetics. <https://www.nature.com/articles/s41588-023-01485-w>.
102. Didriksen, M. *et al.* Large genome-wide association study identifies three novel risk variants for restless legs syndrome. *Commun. Biol.* **3**, 1–9 (2020).
103. Malik, R. *et al.* Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat. Genet.* **50**, 524–537 (2018).
104. Kamada, F. *et al.* A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. *J. Hum. Genet.* **56**, 34–40 (2011).
105. Nakao, T. *et al.* Deep neural network-based computer-assisted detection of cerebral aneurysms in MR angiography. *J. Magn. Reson. Imaging JMRI* **47**, 948–953 (2018).
106. Oermann, E. K. *et al.* Using a Machine Learning Approach to Predict Outcomes after Radiosurgery for Cerebral Arteriovenous Malformations. *Sci. Rep.* **6**, 21161 (2016).
107. Neff, R. A. *et al.* Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals novel mechanisms and targets. *Sci. Adv.* **7**, eabb5398 (2021).
108. Thijssen, E. H. *et al.* Diagnostic value of plasma phosphorylated tau181 in Alzheimer's

- disease and frontotemporal lobar degeneration. *Nat. Med.* **26**, 387–397 (2020).
109. Fehlbauer-Beurdeley, P. *et al.* Validation of AclarusDx™, a blood-based transcriptomic signature for the diagnosis of Alzheimer's disease. *J. Alzheimers Dis. JAD* **32**, 169–181 (2012).
 110. Satoh, J., Yamamoto, Y., Asahina, N., Kitano, S. & Kino, Y. RNA-Seq Data Mining: Downregulation of NeuroD6 Serves as a Possible Biomarker for Alzheimer's Disease Brains. *Dis. Markers* **2014**, 1–10 (2014).
 111. Carling, P. J. *et al.* Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson's disease. *Prog. Neurobiol.* **187**, 101772 (2020).
 112. Aronica, E. *et al.* Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. *Neurobiol. Dis.* **74**, 359–376 (2015).
 113. Morello, G., Spampinato, A. G. & Cavallaro, S. Molecular Taxonomy of Sporadic Amyotrophic Lateral Sclerosis Using Disease-Associated Genes. *Front. Neurol.* **8**, 152 (2017).
 114. Carroll, J. A., Race, B., Williams, K., Striebel, J. & Chesebro, B. RNA-seq and network analysis reveal unique glial gene expression signatures during prion infection. *Mol. Brain* **13**, 71 (2020).
 115. LaPaglia, D. M. *et al.* RNA-Seq investigations of human post-mortem trigeminal ganglia. *Cephalalgia* **38**, 912–932 (2018).
 116. Mathys, H. *et al.* Single-cell transcriptomic analysis of Alzheimer's disease. *Nature* **570**, 332–337 (2019).
 117. Sunkin, S. M. *et al.* Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system. *Nucleic Acids Res.* **41**, D996–D1008 (2013).
 118. Leng, K. *et al.* Molecular characterization of selectively vulnerable neurons in Alzheimer's disease. *Nat. Neurosci.* **24**, 276–287 (2021).
 119. Kamath, T. *et al.* Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease. *Nat. Neurosci.* **25**, 588–595 (2022).
 120. Maynard, K. R. *et al.* Transcriptome-scale spatial gene expression in the human dorsolateral prefrontal cortex. *Nat. Neurosci.* **24**, 425–436 (2021).
 121. Maniatis, S. *et al.* Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. *Science* **364**, 89–93 (2019).
 122. Xu, J. *et al.* Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. *Genome Res.* **31**, 1900–1912 (2021).
 123. Jordão, M. J. C. *et al.* Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. *Science* **363**, eaat7554 (2019).

124. Schafflick, D. *et al.* Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. *Nat. Commun.* **11**, 247 (2020).
125. Wang, P. *et al.* Single-cell transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinson's disease. *Cell Discov.* **7**, 52 (2021).
126. Hara, T. *et al.* Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. *Cancer Cell* **39**, 779-792.e11 (2021).
127. Yang, A. C. *et al.* Dysregulation of brain and choroid plexus cell types in severe COVID-19. *Nature* **595**, 565–571 (2021).
128. Richards, L. M. *et al.* Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity. *Nat. Cancer* **2**, 157–173 (2021).
129. Hovestadt, V. *et al.* Resolving medulloblastoma cellular architecture by single-cell genomics. *Nature* **572**, 74–79 (2019).
130. Liu, X. *et al.* Clinical challenges of tissue preparation for spatial transcriptome. *Clin. Transl. Med.* **12**, e669 (2022).
131. Kulkarni, A., Anderson, A. G., Merullo, D. P. & Konopka, G. Beyond bulk: a review of single cell transcriptomics methodologies and applications. *Curr. Opin. Biotechnol.* **58**, 129–136 (2019).
132. Saunders, A. *et al.* Molecular Diversity and Specializations among the Cells of the Adult Mouse Brain. *Cell* **174**, 1015-1030.e16 (2018).
133. Müller, O. & Rotter, S. Neurotechnology: Current Developments and Ethical Issues. *Front. Syst. Neurosci.* **11**, 93 (2017).
134. Angrick, M. *et al.* Online speech synthesis using a chronically implanted brain-computer interface in an individual with ALS. *MedRxiv Prepr. Serv. Health Sci.* 2023.06.30.23291352 (2023) doi:10.1101/2023.06.30.23291352.
135. Guk, K. *et al.* Evolution of Wearable Devices with Real-Time Disease Monitoring for Personalized Healthcare. *Nanomater. Basel Switz.* **9**, 813 (2019).
136. Jeffrey, K. & Parsonnet, V. Cardiac Pacing, 1960–1985: A Quarter Century of Medical and Industrial Innovation. *Circulation* **97**, 1978–1991 (1998).
137. Safavi, K., Mathews, S. C., Bates, D. W., Dorsey, E. R. & Cohen, A. B. Top-Funded Digital Health Companies And Their Impact On High-Burden, High-Cost Conditions. *Health Aff. Proj. Hope* **38**, 115–123 (2019).
138. Johnson J. *What's Holding Wearables Back? Brodeur Partners.* 2015.
139. Raja, J. M. *et al.* Apple Watch, Wearables, and Heart Rhythm: where do we stand? *Ann. Transl. Med.* **7**, 417 (2019).
140. Minen, M. T. & Stieglitz, E. J. Wearables for Neurologic Conditions: Considerations for Our

- Patients and Research Limitations. *Neurol. Clin. Pract.* **11**, e537–e543 (2021).
141. SAMSON, K. New Wearable Medical Tech Tracks More than Just Steps. (2015).
 142. Bianchi, M. T. Sleep devices: wearables and nearables, informational and interventional, consumer and clinical. *Metabolism*. **84**, 99–108 (2018).
 143. Retnaningsih, R. *et al.* Robotics Applications in Neurology: A Review of Recent Advancements and Future Directions. (2023) doi:10.5281/ZENODO.8062306.
 144. Gassert, R. & Dietz, V. Rehabilitation robots for the treatment of sensorimotor deficits: a neurophysiological perspective. *J. NeuroEngineering Rehabil.* **15**, 46 (2018).
 145. Hobbs, B. & Artemiadis, P. A Review of Robot-Assisted Lower-Limb Stroke Therapy: Unexplored Paths and Future Directions in Gait Rehabilitation. *Front. Neurorobotics* **14**, 19 (2020).
 146. Kleim, J. A. & Jones, T. A. Principles of Experience-Dependent Neural Plasticity: Implications for Rehabilitation After Brain Damage. *J. Speech Lang. Hear. Res.* **51**, (2008).
 147. Oña, E. D., Garcia-Haro, J. M., Jardón, A. & Balaguer, C. Robotics in Health Care: Perspectives of Robot-Aided Interventions in Clinical Practice for Rehabilitation of Upper Limbs. *Appl. Sci.* **9**, 2586 (2019).
 148. Sim, D. Y. Y. & Loo, C. K. Extensive assessment and evaluation methodologies on assistive social robots for modelling human–robot interaction – A review. *Inf. Sci.* **301**, 305–344 (2015).
 149. Cassimatis, N. L., Trafton, J. G., Bugajska, M. D. & Schultz, A. C. Integrating cognition, perception and action through mental simulation in robots. *Robot. Auton. Syst.* **49**, 13–23 (2004).
 150. Laird, J. E., Lebiere, C. & Rosenbloom, P. S. A Standard Model of the Mind: Toward a Common Computational Framework Across Artificial Intelligence, Cognitive Science, Neuroscience, and Robotics. *AI Mag.* **38**, 13–26 (2017).
 151. Müller-Putz, G. R., Scherer, R., Pfurtscheller, G. & Rupp, R. Brain-computer interfaces for control of neuroprostheses: from synchronous to asynchronous mode of operation / Brain-Computer Interfaces zur Steuerung von Neuroprothesen: von der synchronen zur asynchronen Funktionsweise. *Biomed. Tech. Eng.* **51**, 57–63 (2006).
 152. Fletcher, M. D., Thini, N. & Perry, S. W. Enhanced Pitch Discrimination for Cochlear Implant Users with a New Haptic Neuroprosthetic. *Sci. Rep.* **10**, 10354 (2020).
 153. Barrett, J. M., Berlinguer-Palmini, R. & Degenaar, P. Optogenetic approaches to retinal prosthesis. *Vis. Neurosci.* **31**, 345–354 (2014).
 154. Davis, J. A. *et al.* Surgical technique for installing an eight-channel neuroprosthesis for standing. *Clin. Orthop.* 237–252 (2001) doi:10.1097/00003086-200104000-00035.
 155. Triolo, R. J. *et al.* Implanted electrical stimulation of the trunk for seated postural stability and function after cervical spinal cord injury: a single case study. *Arch. Phys. Med. Rehabil.* **90**, 340–347 (2009).

156. Carhart, M. R., Jiping He, Herman, R., D'Luzansky, S. & Willis, W. T. Epidural spinal-cord stimulation facilitates recovery of functional walking following incomplete spinal-cord injury. *IEEE Trans. Neural Syst. Rehabil. Eng.* **12**, 32–42 (2004).
157. Bergey, G. K. *et al.* Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. *Neurology* **84**, 810–817 (2015).
158. Nair, D. R. *et al.* Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. *Neurology* **95**, (2020).
159. “Newronika alphas closed-loop adaptive deep brain stimulation system,” [Online]. Available: <http://www.newronika.com/>, 2021.
160. Gutiérrez-Martínez, J., Toledo-Peral, C., Mercado-Gutiérrez, J., Vera-Hernández, A. & Leija-Salas, L. Neuroprosthesis Devices Based on Micro- and Nanosensors: A Systematic Review. *J. Sens.* **2020**, 1–19 (2020).
161. Dhanasingh, A. & Jolly, C. An overview of cochlear implant electrode array designs. *Hear. Res.* **356**, 93–103 (2017).
162. Chen, J. C. *et al.* A wireless millimetric magnetoelectric implant for the endovascular stimulation of peripheral nerves. *Nat. Biomed. Eng.* **6**, 706–716 (2022).
163. Kirkman, M. A. The role of imaging in the development of neurosurgery. *J. Clin. Neurosci.* **22**, 55–61 (2015).
164. Lin, D. *et al.* Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975-2018. *Front. Oncol.* **11**, (2021).
165. Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. <https://www.hindawi.com/journals/cmml/2017/7064120/>.
166. Galldiks, N. *et al.* Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. *Neuro-Oncol.* **23**, 881–893 (2021).
167. Patel, P. *et al.* MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. *Neuro-Oncol.* **19**, 118–127 (2017).
168. Choi, H. S. *et al.* Glioma Grading Capability: Comparisons among Parameters from Dynamic Contrast-Enhanced MRI and ADC Value on DWI. *Korean J. Radiol.* **14**, 487–492 (2013).
169. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas - Li - 2004 - NMR in Biomedicine - Wiley Online Library. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/nbm.858?casa_token=_D1vPVFZt84AAAAA:FvRVXwwxgi1MKwiv9aTVrQSxZDtnFzWxtZAbSVPlKhc6U79X3pifQj6fy8L-J8sx9VnKySbTaihVrQ.
170. Soun, J. E. *et al.* Artificial Intelligence and Acute Stroke Imaging. *Am. J. Neuroradiol.* **42**, 2–11 (2021).
171. Tang, F.-H., Ng, D. K. S. & Chow, D. H. K. An image feature approach for computer-aided detection of ischemic stroke. *Comput. Biol. Med.* **41**, 529–536 (2011).

172. Abedi, V. *et al.* Novel Screening Tool for Stroke Using Artificial Neural Network. *Stroke* **48**, 1678–1681 (2017).
173. Chen, L., Bentley, P. & Rueckert, D. Fully automatic acute ischemic lesion segmentation in DWI using convolutional neural networks. *NeuroImage Clin.* **15**, 633–643 (2017).
174. Takahashi, N. *et al.* An automated detection method for the MCA dot sign of acute stroke in unenhanced CT. *Radiol. Phys. Technol.* **7**, 79–88 (2014).
175. Barreira, C. *et al.* E-108 Aladin study: automated large artery occlusion detection in stroke imaging study – a multicenter analysis. in *Electronic Poster Abstracts A101.2-A102* (BMJ Publishing Group Ltd., 2018). doi:10.1136/neurintsurg-2018-SNIS.184.
176. Nagel, S. *et al.* e-ASPECTS software is non-inferior to neuroradiologists in applying the ASPECT score to computed tomography scans of acute ischemic stroke patients. *Int. J. Stroke* **12**, 615–622 (2017).
177. Wu, O. *et al.* Predicting tissue outcome in acute human cerebral ischemia using combined diffusion- and perfusion-weighted MR imaging. *Stroke* **32**, 933–942 (2001).
178. Ho, K. C. Predicting ischemic stroke tissue fate using a deep convolutional neural network on source magnetic resonance perfusion images. *J. Med. Imaging* **6**, 1 (2019).
179. Young, P. N. E. *et al.* Imaging biomarkers in neurodegeneration: current and future practices. *Alzheimers Res. Ther.* **12**, 49 (2020).
180. Cohen, A. D. *et al.* Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. *Adv. Pharmacol. San Diego Calif* **64**, 27–81 (2012).
181. Brier, M. R. *et al.* Tau and A β imaging, CSF measures, and cognition in Alzheimer’s disease. *Sci. Transl. Med.* **8**, 338ra66 (2016).
182. Kato, T., Inui, Y., Nakamura, A. & Ito, K. Brain fluorodeoxyglucose (FDG) PET in dementia. *Ageing Res. Rev.* **30**, 73–84 (2016).
183. Zhang, Y. *et al.* Detection of subjects and brain regions related to Alzheimer’s disease using 3D MRI scans based on eigenbrain and machine learning. *Front. Comput. Neurosci.* **9**, 66 (2015).
184. Ding, Y. *et al.* A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18F-FDG PET of the Brain. *Radiology* **290**, 456–464 (2019).
185. Saravanan, S. *et al.* A Systematic Review of Artificial Intelligence (AI) Based Approaches for the Diagnosis of Parkinson’s Disease. *Arch. Comput. Methods Eng.* **29**, 3639–3653 (2022).
186. Georgiopoulos, C. *et al.* A study of neural activity and functional connectivity within the olfactory brain network in Parkinson’s disease. *NeuroImage Clin.* **23**, 101946 (2019).
187. Singh, G., Vadera, M., Samavedham, L. & Lim, E. C.-H. Multiclass Diagnosis of Neurodegenerative Diseases: A Neuroimaging Machine-Learning-Based Approach. *Ind. Eng. Chem. Res.* **58**, 11498–11505 (2019).

188. Kazeminejad, A., Golbabaie, S. & Soltanian-Zadeh, H. Graph theoretical metrics and machine learning for diagnosis of Parkinson's disease using rs-fMRI. in *2017 Artificial Intelligence and Signal Processing Conference (AISP)* 134–139 (IEEE, Shiraz, 2017). doi:10.1109/AISP.2017.8324124.
189. Zeng, L.-L. *et al.* Differentiating Patients with Parkinson's Disease from Normal Controls Using Gray Matter in the Cerebellum. *The Cerebellum* **16**, 151–157 (2017).
190. Wabnegger, A. *et al.* Facial Emotion Recognition in Parkinson's Disease: An fMRI Investigation. *PLOS ONE* **10**, e0136110 (2015).

Figures




Figure 1. Fields of advances in the last half-century in neurology.




Figure 2. Timeline of key technological advances in the last 25 years.




Figure 3. Summary of neurology-related data-science-based advances in the last half-century.




Figure 4. Summary of neurotechnology advances in the last half century


Supplementary Files

Untitled.


URL: <http://asset.jmir.pub/assets/94ca139c073188559ae2859860f65fab.docx>

Figures


Fields of advances in the last half-century in neurology.



Timeline of key advances in neuroinformatics in the last half-century.



Summary of neurology-related data-science-based advances in the last half-century.



Summary of neurotechnology advances in the last half-century.

